Oculis Holding AG (OCS) Non-Current Assets (2021 - 2026)
Oculis Holding AG (OCS) posted quarterly Non-Current Assets of $21.7 million for Q1 2026, up 26.56% year-over-year from $17.1 million in Q1 2025, and up 1.36% quarter-over-quarter from $21.4 million in Q4 2025.
Analysis
Oculis Holding AG (OCS) Non-Current Assets (2021 - 2026) Analysis & Trends
Oculis Holding AG's Non-Current Assets history runs 6 years deep, the most recent figure standing at $21.7 million for Q1 2026.
- In Q1 2026, Non-Current Assets rose 26.56% year-over-year to $21.7 million; the TTM figure through Mar 2026 stood at $21.7 million (up 26.56% YoY), while the FY2025 annual figure was $20.6 million, up 17.22% from the prior year.
- Non-Current Assets for Q1 2026 stood at $21.7 million, up from $21.4 million in the prior quarter.
- The five-year high for Non-Current Assets was $21.7 million in Q1 2026, with the low at $13.9 million in Q4 2022.
- The 5-year median for Non-Current Assets is $16.3 million (2024), against an average of $17.2 million.
- The sharpest annual moves came in 2024 and 2025: Non-Current Assets grew 4.02% in 2024, then climbed 29.88% in 2025.
- Oculis Holding AG's Non-Current Assets stood at $13.9 million in 2022, then climbed by 8.08% to $15.0 million in 2023, then climbed by 17.34% to $17.6 million in 2024, then gained by 21.08% to $21.4 million in 2025, then advanced by 1.36% to $21.7 million in 2026.
- Business Quant data shows OCS's Non-Current Assets at $21.7 million in Q1 2026, $21.4 million in Q4 2025, and $21.2 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 5.15 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 294.93 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 1.96 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 938.60 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 18.06 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Oculis Holding AG | 634.75 Mn | 345.87 Mn | - | 21.85 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 21.85 Mn |
| Mar 31, 2026 | 21.65 Mn |
| Dec 31, 2025 | 21.36 Mn |
| Sep 30, 2025 | 21.16 Mn |
| Jun 30, 2025 | 18.63 Mn |
| Mar 31, 2025 | 17.11 Mn |
| Dec 31, 2024 | 17.64 Mn |
| Sep 30, 2024 | 16.29 Mn |
| Jun 30, 2024 | 15.59 Mn |
| Mar 31, 2024 | 15.20 Mn |
| Dec 31, 2023 | 15.04 Mn |
| Sep 30, 2023 | 15.22 Mn |
| Jun 30, 2023 | 14.99 Mn |
| Dec 31, 2022 | 13.91 Mn |
| Dec 31, 2021 | 10.91 Mn |